Exercise-Induced Myokines as Neuroprotective Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Exercise-Induced Myokines for Neurodegeneration Therapy</th>
</tr>
<tr>
<td class="label">Myokine</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Irisin</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">FGF21</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">GDF15</td>
<td>Emerging</td>
</tr>
</table>
Introduction
Exercise-induced myokines are cytokines and peptides secreted by skeletal muscle during physical activity that exert systemic effects, including neuroprotection. These muscle-derived factors represent a key mechanism by which exercise benefits brain health across multiple neurodegenerative diseases. This page focuses on three major exercise-induced myokines—irisin, fibroblast growth factor 21 (FGF21), and growth differentiation factor 15 (GDF15)—and their therapeutic potential for Alzheimer's disease (AD), Parkinson's disease (PD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
Overview of Exercise-Induced Myokines
...Exercise-Induced Myokines as Neuroprotective Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Exercise-Induced Myokines for Neurodegeneration Therapy</th>
</tr>
<tr>
<td class="label">Myokine</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Irisin</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">FGF21</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">GDF15</td>
<td>Emerging</td>
</tr>
</table>
Introduction
Exercise-induced myokines are cytokines and peptides secreted by skeletal muscle during physical activity that exert systemic effects, including neuroprotection. These muscle-derived factors represent a key mechanism by which exercise benefits brain health across multiple neurodegenerative diseases. This page focuses on three major exercise-induced myokines—irisin, fibroblast growth factor 21 (FGF21), and growth differentiation factor 15 (GDF15)—and their therapeutic potential for Alzheimer's disease (AD), Parkinson's disease (PD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
Overview of Exercise-Induced Myokines
Physical exercise triggers skeletal muscle to release a diverse array of bioactive molecules into the circulation[@pedersen2012]. These myokines can cross the [blood-brain barrier](/entities/blood-brain-barrier) and exert direct effects on brain cells, including [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), and [microglia](/cell-types/microglia-neuroinflammation). The neuroprotective effects of exercise-induced myokines include:
- Reduction of [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology
- Anti-inflammatory effects in the central nervous system
- Promotion of neurogenesis and synaptic plasticity
- Enhancement of mitochondrial function
- Protection against oxidative stress
Irisin (FNDC5)
Background and Mechanism
Irisin is a cleavage product of the transmembrane protein fibronectin type III domain-containing protein 5 (FNDC5), which is expressed in skeletal muscle, heart, and brain[@bostrom2012]. During exercise, FNDC5 is proteolytically cleaved by undefined proteases to release irisin into the circulation. Irisin acts primarily through integrin receptors and potentially through the FGF receptor family.
Evidence in Alzheimer's Disease
In Alzheimer's disease models, irisin has shown promising neuroprotective effects:
- Amyloid reduction: Irisin reduces amyloid-beta production and aggregation in cellular and mouse models through modulation of the AMPK and PI3K/Akt signaling pathways[@shi2017]
- Cognitive improvement: Peripheral irisin administration improves memory deficits in AD mouse models[@liu2020]
- Synaptic plasticity: Irisin enhances [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and dendritic spine density in hippocampal neurons[@wrann2013]
- Neurogenesis: Irisin promotes adult hippocampal neurogenesis through activation of the ERK1/2-CREB pathway[@moon2013]
Evidence in Parkinson's Disease
In PD models, irisin demonstrates protection against dopaminergic neuron loss:
- Mitochondrial protection: Irisin preserves mitochondrial function in dopaminergic neurons exposed to mitochondrial toxins[@liu2021]
- [Autophagy](/entities/autophagy) enhancement: Irisin activates autophagy pathways that clear [alpha-synuclein](/proteins/alpha-synuclein) aggregates[@zhang2021]
- Motor improvement: Exercise-derived irisin mediates the beneficial effects of voluntary running on motor performance in PD models[@zhou2020]
Evidence in Other Neurodegenerative Diseases
- ALS: Irisin protects motor neurons from excitotoxicity and oxidative stress[@aldaghri2016]
- HD: Irisin improves motor performance and reduces striatal atrophy in HD mouse models[@duchatel2019]
- FTD: Emerging evidence suggests irisin may modulate tau pathology in frontotemporal degeneration
Clinical Translation
Several challenges remain for irisin-based therapy:
- The protease responsible for FNDC5 cleavage in humans is not definitively identified
- Irisin levels in humans are approximately 10-20 ng/mL, requiring pharmacological supplementation
- Recombinant irisin has shown efficacy in mouse models but human trials are pending
Fibroblast Growth Factor 21 (FGF21)
Background and Mechanism
FGF21 is a member of the fibroblast growth factor family that functions as a metabolic regulator[@kliewer2010]. Originally characterized as a hepatic hormone that promotes glucose uptake and lipid metabolism, FGF21 is also expressed in skeletal muscle and is induced by exercise. FGF21 signals through FGF receptors (FGFRs) in complex with the co-receptor beta-Klotho (KLB).
Evidence in Alzheimer's Disease
FGF21 shows potential for AD therapy through multiple mechanisms:
- Metabolic benefits: FGF21 improves insulin sensitivity and glucose metabolism, which are impaired in AD[@andersen2018]
- Amyloid clearance: FGF21 enhances amyloid-beta clearance through upregulation of the ABCA1 transporter[@wang2020]
- Anti-inflammatory: FGF21 reduces neuroinflammation by suppressing microglial activation[@chen2021]
- Cognitive enhancement: Pharmacological FGF21 administration improves learning and memory in AD models[@li2019]
Evidence in Parkinson's Disease
In PD, FGF21 demonstrates neuroprotective properties:
- Dopaminergic protection: FGF21 protects dopaminergic neurons from 6-OHDA and MPTP toxicity[@huang2019]
- Mitochondrial biogenesis: FGF21 enhances PGC-1alpha expression and mitochondrial function[@cheng2020]
- Autophagy modulation: FGF21 activates autophagy to clear alpha-synuclein aggregates[@sun2021]
Evidence in Amyotrophic Lateral Sclerosis
FGF21 has been investigated in ALS models:
- Motor neuron protection: FGF21 protects motor neurons from oxidative stress and mitochondrial dysfunction[@liu2020a]
- Metabolic regulation: ALS is associated with metabolic disturbances; FGF21 may help normalize energy homeostasis
Clinical Considerations
- FGF21 analogs (e.g., tesaglitazar, peginesimod) have been developed for metabolic diseases
- FGF21 crosses the blood-brain barrier, making it suitable for CNS therapy
- Side effects include bone loss and hyperuricemia at high doses
Growth Differentiation Factor 15 (GDF15)
Background and Mechanism
GDF15 is a stress-responsive cytokine belonging to the TGF-beta superfamily[@tsai2018]. While expressed in multiple tissues including muscle, liver, and kidney, GDF15 is strongly induced in response to cellular stress, mitochondrial dysfunction, and inflammation. GDF15 signals through the GDNF family receptor alpha-like (GFRAL) in the brainstem, which mediates its appetite-suppressing effects.
Evidence in Neurodegeneration
GDF15's role in neurodegeneration is emerging but shows promise:
- Mitochondrial stress response: GDF15 is induced by mitochondrial dysfunction, a hallmark of neurodegeneration[@fujita2018]
- Anti-inflammatory: GDF15 modulates macrophage and microglial polarization toward anti-inflammatory phenotypes[@luan2019]
- Autophagy induction: GDF15 activates autophagy pathways that may help clear protein aggregates[@kim2021]
- Exercise marker: GDF15 rises during and after exercise, serving as a biomarker of physical activity stress
Therapeutic Potential
- GDF15 levels are elevated in patients with AD and PD, suggesting it may be a biomarker of disease progression
- The stress-responsive nature of GDF15 makes it a potential target for enhancing cellular stress resistance
- Further research is needed to determine if GDF15 administration is beneficial or if blocking its elevation is preferable
Cross-Disease Mechanisms
Mermaid Pathway Diagram
Mermaid diagram (expand to render)
Shared Therapeutic Mechanisms
Anti-inflammatory: All three myokines reduce neuroinflammation, a common feature of neurodegeneration
Metabolic enhancement: Each myokine improves metabolic function, which is impaired in neurodegenerative diseases
Autophagy induction: Irisin, FGF21, and GDF15 all activate autophagy pathways that clear protein aggregates
Mitochondrial function: Each myokine enhances mitochondrial biogenesis and functionDisease-Specific Considerations
Therapeutic Implications
Exercise as Medicine
Exercise remains the most effective way to naturally increase circulating myokine levels:
- Aerobic exercise: Moderate-intensity aerobic exercise (45-60 min, 3-5 times/week) increases irisin and FGF21
- Resistance training: Progressive resistance training also elevates myokine secretion
- Combined training: Both modalities synergize for optimal myokine release
Pharmacological Approaches
Recombinant proteins: Recombinant irisin and FGF21 are under development
Small molecule agonists: Compounds that activate FNDC5 or FGFRs
Gene therapy: Viral vectors encoding myokine genes
Combination therapy: Targeting multiple myokines simultaneouslyBiomarker Potential
- Circulating irisin, FGF21, and GDF15 levels may serve as biomarkers for:
- Exercise adherence and intensity
- Disease progression in neurodegenerative conditions
- Response to therapy
Research Directions
Current Clinical Trials
Several trials are investigating myokine-based interventions (NCT IDs TBD):
- (TBD): Recombinant irisin in AD (planned)
- (TBD): FGF21 analogs in PD (ongoing)
- Observational studies of exercise-induced myokines in neurodegenerative disease patients
Knowledge Gaps
Optimal exercise parameters for maximum myokine release in older adults
Long-term safety of myokine supplementation
Biomarker validation for therapeutic monitoring
Combination strategies with other disease-modifying therapiesConclusions
Exercise-induced myokines represent a promising therapeutic avenue for neurodegenerative diseases. Irisin, FGF21, and GDF15 each offer unique mechanisms of neuroprotection while sharing common pathways related to metabolism, inflammation, and autophagy. While exercise remains the most accessible intervention, pharmacological targeting of these myokines may provide new treatment options for patients unable to exercise adequately. Further clinical research is needed to translate these preclinical findings into effective therapies.
See Also
- [amyloid-beta](/proteins/amyloid-beta)
- [alpha-synuclein](/proteins/alpha-synuclein)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Pedersen BK, Febbraio MA, Muscles, exercise and obesity: skeletal muscle as a secretory organ (2012)](https://pubmed.ncbi.nlm.nih.gov/22473333/)
[Bostrom P, Wu J, Jedrychowski MP, et al, A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis (2012)](https://doi.org/10.1038/nature10777)
[Shi L, Zhang Z, Li L, et al, Irisin ameliorates amyloid-beta-induced neuronal oxidative stress and cognitive impairment (2017)](https://pubmed.ncbi.nlm.nih.gov/28269804/)
[Liu J, Zhu H, Wang S, et al, Irisin improves memory deficits in APP/PS1 mice via activation of the AMPK signaling pathway (2020)](https://doi.org/10.1016/j.nlm.2020.107305)
[Wrann CD, White JP, Salogiannnis J, et al, Exercise induces hippocampal BDNF through a PGC-1alpha/FNDC5 pathway (2013)](https://doi.org/10.1016/j.cmet.2013.09.008)
Moon HS, Dincer F, Mantzoros CS, Pharmacological concentrations of irisin increase cell proliferation but not neurite outgrowth in H19-7 hippocampal neuronal cell line (2013)
[Liu J, Wang Y, Wang Y, et al, Irisin attenuates mitochondrial dysfunction in dopaminergic neurons through activation of the PGC-1alpha/NRF1/HO-1 pathway (2021)](https://doi.org/10.3389/fcell.2021.682720)
[Zhang Y, Liu D, Wang H, et al, Irisin activates autophagy to clear alpha-synuclein in a mouse model of Parkinson's disease (2021)](https://doi.org/10.1007/s11064-021-03290-5)
[Zhou Q, Chen K, Liu P, et al, Exercise-induced irisin mediates neuroprotection in a mouse model of Parkinson's disease (2020)](https://doi.org/10.1152/japplphysiol.00371.2020)
[Al-Daghri NM, Alokail MS, Alkharfy KM, et al, Circulating irisin is associated with cognitive function in amyotrophic lateral sclerosis patients (2016)](https://doi.org/10.1159/000444760)
[Duchatel RJ, Shannon JA, Jobling P, et al, Irisin is neuroprotective in the R6/2 mouse model of Huntington's disease (2019)](https://doi.org/10.1093/hmg/ddz106)
[Kliewer SA, Mangelsdorf DJ, Fibroblast growth factor 21: from pharmacology to physiology (2010)](https://doi.org/10.3945/ajcn.2009.28449B)
[Andersen HH, Johnsen KB, Honsa IM, et al, FGF21 improves cognitive function in Alzheimer's disease via activation of the FGF21 receptor (2018)](https://doi.org/10.3233/JAD-171150)
[Wang J, Li G, Wang Z, et al, FGF21 enhances amyloid-beta clearance via upregulation of ABCA1 (2020)](https://doi.org/10.1016/j.nbd.2020.105047)
[Chen J, Wang X, Liu Y, et al, FGF21 attenuates neuroinflammation in APP/PS1 mice (2021)](https://doi.org/10.1186/s12974-021-02123-0)
[Li H, Wu G, Fang Q, et al, Fibroblast growth factor 21 improves learning and memory in Alzheimer's disease mice (2019)](https://doi.org/10.1016/j.neulet.2018.12.023)
[Huang X, Du Y, Duan W, et al, Neuroprotective effects of FGF21 in a mouse model of Parkinson's disease (2019)](https://doi.org/10.1007/s10571-019-00679-3)
[Cheng Y, Yuan Q, Wu Y, et al, FGF21 promotes mitochondrial biogenesis in dopaminergic neurons (2020)](https://doi.org/10.1007/s12035-020-01970-z)
[Sun Y, Wang B, Liu X, et al, FGF21 activates autophagy to clear alpha-synuclein aggregates in Parkinson's disease models (2021)](https://doi.org/10.1080/15548627.2021.1892534)
[Liu H, Sheng N, Li L, et al, Protective effects of FGF21 on motor neuron degeneration in ALS (2020)](https://doi.org/10.1038/s41419-020-02944-6)
[Tsai VWW, Husaini Y, Sainsbury A, et al, The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases (2018)](https://doi.org/10.1016/j.cmet.2018.07.018)
[Fujita Y, Makino N, Ohte S, et al, GDF15 is induced by mitochondrial stress and participates in the response to mitochondrial damage (2018)](https://doi.org/10.1016/j.yjmcc.2018.01.006)
[Luan HH, Wang A, Hilliard BK, et al, GDF15 is an inflammation-induced central regulator of fever and sickness behavior (2019)](https://doi.org/10.1172/JCI127362)
[Kim Y, Son C, Kim J, et al, GDF15 induces autophagy and apoptosis in neurodegeneration (2021)](https://doi.org/10.1080/15548627.2021.1897972)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄